Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
68.26
-3.19 (-4.46%)
At close: Apr 1, 2025, 4:00 PM
68.01
-0.25 (-0.37%)
After-hours: Apr 1, 2025, 4:47 PM EDT

Soleno Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2015
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2015
Selling, General & Admin
105.8613.489.8410.818.76
Upgrade
Research & Development
78.5725.1915.2721.4523.19
Upgrade
Operating Expenses
184.4338.6725.1132.2631.95
Upgrade
Operating Income
-184.43-38.67-25.11-32.26-31.95
Upgrade
Interest Expense
-0.23----
Upgrade
Interest & Investment Income
12.052.580.30.110.01
Upgrade
Other Non Operating Income (Expenses)
--0.180.030.5111.64
Upgrade
EBT Excluding Unusual Items
-172.61-36.27-24.78-31.64-20.3
Upgrade
Other Unusual Items
-3.24-2.710.710.73-4.34
Upgrade
Pretax Income
-175.85-38.99-24.07-30.91-24.64
Upgrade
Earnings From Continuing Operations
-175.85-38.99-24.07-30.91-24.64
Upgrade
Net Income
-175.85-38.99-24.07-30.91-24.64
Upgrade
Net Income to Common
-175.85-38.99-24.07-30.91-24.64
Upgrade
Shares Outstanding (Basic)
4016854
Upgrade
Shares Outstanding (Diluted)
4016854
Upgrade
Shares Change (YoY)
143.61%96.40%57.90%27.39%83.41%
Upgrade
EPS (Basic)
-4.38-2.36-2.87-5.81-5.90
Upgrade
EPS (Diluted)
-4.38-2.36-2.87-5.81-5.90
Upgrade
Free Cash Flow
-69.31-24.94-20.79-27.79-25.23
Upgrade
Free Cash Flow Per Share
-1.73-1.51-2.48-5.23-6.04
Upgrade
EBITDA
-182.44-36.71-23.15-30.3-30
Upgrade
D&A For EBITDA
1.991.961.961.961.95
Upgrade
EBIT
-184.43-38.67-25.11-32.26-31.95
Upgrade
Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q